Skip to main content

Market Overview

Sanofi-AstraZeneca's Nirsevimab Hits Primary Endpoint Goal In Late-Stage RSV Disease In Infants

Sanofi-AstraZeneca's Nirsevimab Hits Primary Endpoint Goal In Late-Stage RSV Disease In Infants
  • Sanofi SA (NASDAQ: SNY) and AstraZeneca Plc’s (NASDAQ: AZN) monoclonal antibody (mAb) nirsevimab has reached its primary endpoint in a Phase 3 trial, demonstrating protection against respiratory syncytial virus disease (RSV) in healthy infants.
  • The data comes earlier than anticipated; regulatory submissions for all-infant indications are expected to begin in 2022.
  • Nirsevimab, an investigational extended half-life mAb is designed to protect infants entering their first RSV season when they are at a higher risk for developing severe RSV disease.
  • In the Phase 3 MELODY trial, nirsevimab reduced lower respiratory tract infections (LRTI) requiring medical attention due to RSV in healthy preterm and term infants.
  • There were no clinically meaningful differences observed in the safety results between the nirsevimab and placebo groups. The overall safety profile for nirsevimab in the trial remained consistent with previously reported results.
  • Sanofi and AstraZeneca are also evaluating nirsevimab in a Phase 3 trial to assess the safety and tolerability of the mAb compared to Sobi’s Synagis (palivizumab) among preterm infants and children with chronic lung disease (CLD) and congenital heart disease (CHD) entering their first and second RSV seasons.
  • Price Action: AZN shares are up 0.63% at $52.59, while SNY stock is down 0.06% at $51.65 in the premarket on the last check Monday.

Related Articles (AZN + SNY)

View Comments and Join the Discussion!

Posted-In: Briefs RSV DiseaseBiotech News Health Care General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at